184 related articles for article (PubMed ID: 19318419)
21. HLA-E is expressed on trophoblast and interacts with CD94/NKG2 receptors on decidual NK cells.
King A; Allan DS; Bowen M; Powis SJ; Joseph S; Verma S; Hiby SE; McMichael AJ; Loke YW; Braud VM
Eur J Immunol; 2000 Jun; 30(6):1623-31. PubMed ID: 10898498
[TBL] [Abstract][Full Text] [Related]
22. Anti-EGFR antibody cetuximab enhances the cytolytic activity of natural killer cells toward osteosarcoma.
Pahl JH; Ruslan SE; Buddingh EP; Santos SJ; Szuhai K; Serra M; Gelderblom H; Hogendoorn PC; Egeler RM; Schilham MW; Lankester AC
Clin Cancer Res; 2012 Jan; 18(2):432-41. PubMed ID: 22090361
[TBL] [Abstract][Full Text] [Related]
23. Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers.
Wu L; Parton A; Lu L; Adams M; Schafer P; Bartlett JB
Cancer Immunol Immunother; 2011 Jan; 60(1):61-73. PubMed ID: 20848094
[TBL] [Abstract][Full Text] [Related]
24. Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC).
Correale P; Marra M; Remondo C; Migali C; Misso G; Arcuri FP; Del Vecchio MT; Carducci A; Loiacono L; Tassone P; Abbruzzese A; Tagliaferri P; Caraglia M
Eur J Cancer; 2010 Jun; 46(9):1703-11. PubMed ID: 20399639
[TBL] [Abstract][Full Text] [Related]
25. Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer.
Kono K; Takahashi A; Ichihara F; Sugai H; Fujii H; Matsumoto Y
Cancer Res; 2002 Oct; 62(20):5813-7. PubMed ID: 12384543
[TBL] [Abstract][Full Text] [Related]
26. Transgenic expression of HLA-E single chain trimer protects porcine endothelial cells against human natural killer cell-mediated cytotoxicity.
Lilienfeld BG; Crew MD; Forte P; Baumann BC; Seebach JD
Xenotransplantation; 2007 Mar; 14(2):126-34. PubMed ID: 17381687
[TBL] [Abstract][Full Text] [Related]
27. miR-143 or miR-145 overexpression increases cetuximab-mediated antibody-dependent cellular cytotoxicity in human colon cancer cells.
Gomes SE; Simões AE; Pereira DM; Castro RE; Rodrigues CM; Borralho PM
Oncotarget; 2016 Feb; 7(8):9368-87. PubMed ID: 26824186
[TBL] [Abstract][Full Text] [Related]
28. Disruption of cell-cell adhesion enhances antibody-dependent cellular cytotoxicity: implications for antibody-based therapeutics of cancer.
Green SK; Karlsson MC; Ravetch JV; Kerbel RS
Cancer Res; 2002 Dec; 62(23):6891-900. PubMed ID: 12460904
[TBL] [Abstract][Full Text] [Related]
29. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines.
Roda JM; Joshi T; Butchar JP; McAlees JW; Lehman A; Tridandapani S; Carson WE
Clin Cancer Res; 2007 Nov; 13(21):6419-28. PubMed ID: 17962339
[TBL] [Abstract][Full Text] [Related]
30. Comparative study of gene expression by cDNA microarray in human colorectal cancer tissues and normal mucosa.
Bianchini M; Levy E; Zucchini C; Pinski V; Macagno C; De Sanctis P; Valvassori L; Carinci P; Mordoh J
Int J Oncol; 2006 Jul; 29(1):83-94. PubMed ID: 16773188
[TBL] [Abstract][Full Text] [Related]
31. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
[TBL] [Abstract][Full Text] [Related]
32. Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells.
Wang W; Nishioka Y; Ozaki S; Jalili A; Verma VK; Hanibuchi M; Abe S; Minakuchi K; Matsumoto T; Sone S
Lung Cancer; 2009 Jan; 63(1):23-31. PubMed ID: 18524412
[TBL] [Abstract][Full Text] [Related]
33. Selenite induces posttranscriptional blockade of HLA-E expression and sensitizes tumor cells to CD94/NKG2A-positive NK cells.
Enqvist M; Nilsonne G; Hammarfjord O; Wallin RP; Björkström NK; Björnstedt M; Hjerpe A; Ljunggren HG; Dobra K; Malmberg KJ; Carlsten M
J Immunol; 2011 Oct; 187(7):3546-54. PubMed ID: 21890659
[TBL] [Abstract][Full Text] [Related]
34. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
Wong SF
Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
[TBL] [Abstract][Full Text] [Related]
35. Cetuximab ± chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro.
Correale P; Botta C; Cusi MG; Del Vecchio MT; De Santi MM; Gori Savellini G; Bestoso E; Apollinari S; Mannucci S; Marra M; Abbruzzese A; Aquino A; Turriziani M; Bonmassar L; Caraglia M; Tagliaferri P
Int J Cancer; 2012 Apr; 130(7):1577-89. PubMed ID: 21618510
[TBL] [Abstract][Full Text] [Related]
36. Expression of NK cell receptors on decidual T cells in human pregnancy.
Tilburgs T; van der Mast BJ; Nagtzaam NM; Roelen DL; Scherjon SA; Claas FH
J Reprod Immunol; 2009 Jun; 80(1-2):22-32. PubMed ID: 19394706
[TBL] [Abstract][Full Text] [Related]
37. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity.
van Meerten T; van Rijn RS; Hol S; Hagenbeek A; Ebeling SB
Clin Cancer Res; 2006 Jul; 12(13):4027-35. PubMed ID: 16818702
[TBL] [Abstract][Full Text] [Related]
38. CD94/NKG2C is a killer effector molecule in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.
Morel E; Escamochero S; Cabañas R; Díaz R; Fiandor A; Bellón T
J Allergy Clin Immunol; 2010 Mar; 125(3):703-10, 710.e1-710.e8. PubMed ID: 20132973
[TBL] [Abstract][Full Text] [Related]
39. Vascular endothelial growth factor partially inhibits the trastuzumab-mediated antibody-dependent cellular cytotoxicity of human monocytes.
Mimura K; Kono K; Takahashi A; Kawaguchi Y; Mizukami Y; Fujii H
Oncology; 2007; 72(3-4):172-80. PubMed ID: 18097168
[TBL] [Abstract][Full Text] [Related]
40. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells.
Fischer L; Penack O; Gentilini C; Nogai A; Muessig A; Thiel E; Uharek L
Exp Hematol; 2006 Jun; 34(6):753-9. PubMed ID: 16728280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
